Nanomerics
Develops polymer-based drug and gene delivery technologies for pharmaceutical therapies in ophthalmology and CNS conditions
Highlights
- New on EvolcAdded 2026-11-08
About Nanomerics
Nanomerics develops precision medicines using its Molecular Envelope Technology (MET) platform, which uses biocompatible polymer nanoparticles to deliver drugs across tissue barriers. Its METfect platform supports non-viral intranasal delivery of genetic therapies to the brain.
The company is a clinical-stage biopharmaceutical business focused on ophthalmology and central nervous system conditions. It was founded in 2010 as a spinout from UCL, the University of Glasgow and the University of Strathclyde, and is headquartered in London.
Product: Molecular Envelope Technology for drug delivery and METfect for non-viral intranasal gene delivery to the brain.
Jobs at Nanomerics
More biotech & pharma companies
Nanosyrinx
Develops targeted intracellular delivery of protein therapeutics for biotech and pharmaceutical drug developersNew on EvolcNanovery
DNA nanorobot assays for biotech and life sciences researchers quantifying RNA therapeutics and nucleic acid biomarkersNew on EvolcNeobe Therapeutics
Engineers live bacterial therapeutics to help immunotherapies reach solid tumours in patients with immune-excluded cancersNew on EvolcNeoceuticals
Paediatric and specialist oral medicines and nutritional products for healthcare markets in the UK and overseasNew on EvolcNeon Healthcare
Supplies prescription medicines to hospitals, pharmacies and other healthcare providersNew on EvolcNeovac
Develops lipid platforms and formulation kits for researchers advancing RNA therapeuticsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.